Digital Diagnostics is recognized in a Forbes article exploring how AI is reshaping ophthalmology.
The article highlights autonomous AI for diabetic retinopathy diagnosis as the clearest example of AI successfully moving from concept to real-world clinical use—and credits Digital Diagnostics’ Founder and Executive Chairman, Michael D. Abramoff, MD, PhD, for pioneering the work that led to LumineticsCore®, the first FDA-cleared autonomous AI system in healthcare.